Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. (2018)

First Author: Quek L
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41591-018-0115-6

PubMed Identifier: 30013198

Publication URI: http://europepmc.org/abstract/MED/30013198

Type: Journal Article/Review

Volume: 24

Parent Publication: Nature medicine

Issue: 8

ISSN: 1078-8956